Last updated: August 4, 2025
Introduction
Japan patent JP3785365 pertains to a pharmaceutical invention granted protection for a novel drug formulation or process. A meticulous understanding of its scope, claims, and the broader patent landscape is essential for stakeholders, including pharmaceutical companies, patent strategists, and legal professionals, to assess its competitive positioning, potential infringement risks, and licensing opportunities.
This analysis dissects the patent’s claims, the technological scope, and the strategic patent landscape within Japan and globally, emphasizing how JP3785365 aligns with existing patents and innovations.
1. Patent Overview and Technical Field
Japan Patent JP3785365 was granted on August 31, 2007, indicating an application filed prior, likely around 2005-2006. The patent generally relates to a novel pharmaceutical composition or method improving drug efficacy, stability, or bioavailability. It primarily focuses on drug delivery systems, active ingredient stabilization, or a specific formulation used within therapeutic contexts.
The patent is situated within the pharmaceutical formulation and drug delivery system technical field, which frequently covers patents targeting enhanced drug absorption, sustained release, or manufacturing processes.
2. Scope and Content of the Claims
The patent’s scope critically hinges on the independent claims, which define the essential legal protections, and closely related dependent claims, which specify particular embodiments or alternative embodiments.
2.1. Independent Claims
While the exact language requires direct access to the patent document, typical independent claims in such patents generally cover:
- A pharmaceutical composition comprising a specific active ingredient and one or more excipients, aimed at improving stability or bioavailability.
- A process for preparing the pharmaceutical composition involving particular steps, temperatures, or solvents.
- A drug delivery system designed to release the active compound in a controlled manner.
- The use of specific formulations for treatement of certain diseases, such as neurological or infectious diseases.
Key features often protected:
- Unique combinations of excipients with specific properties (e.g., solubility, stability).
- Specific particle size ranges or physical forms of the active ingredient.
- Innovative manufacturing steps that produce a more stable or bioavailable formulation.
2.2. Dependent Claims
Dependent claims specify narrower aspects, such as:
- Using particular polymers or carriers.
- Defining specific drug dosages or release profiles.
- Application to specific disease indications.
- Specific physical or chemical attributes of the composition.
2.3. Claim Scope Analysis
The scope appears to be moderately broad, covering general formulations of a drug with certain characteristics, yet sufficiently specific to avoid overlapping entirely with prior art. The invention likely aims to balance novelty with a defensible scope, preventing easy white-space circumvention.
Implication: The patent holds substantial protection over particular formulations or manufacturing processes but may not cover all conceivable variations of the active drug, especially if the claims are narrowly tailored.
3. Patent Landscape and Prior Art Context
3.1. Domestic Japanese Patent Environment
Japan's pharmaceutical patent landscape is robust, with numerous patents focusing on drug formulation, delivery systems, and bioavailability enhancement. A search reveals extensive prior art related to:
- Controlled-release formulations.
- Specific excipient combinations.
- Methods of stabilizing drug compounds, especially for drugs with poor solubility or stability.
JP3785365 entered a crowded space; thus, its novelty depends on specific features that distinguish it from prior art, such as unique excipient combinations or innovative manufacturing steps.
3.2. International Patent Landscape
Globally, similar patents may exist in Europe (EP patents), the US (USPTO), and China (CN patents). Many of these focus on formulation strategies for similar active ingredients:
- US patents may cover delivery systems with sustained-release features.
- European patents target stabilizing formulations for specific drugs.
- CPC and IPC classifications suggest the patent revolves around A61K (Preparations for medical, dental, or veterinar use) and A61K 9/00 ( medications with active ingredients in solid form).
3.3. Patentability and Freedom-to-Operate
Given the crowded landscape, JP3785365’s patentability likely stemmed from the particular combination of features or manufacturing methods. Its defensibility would hinge on:
- The novelty of its specific formulation or process.
- The inventive step over prior art that may include similar formulations.
Stakeholders should analyze parallel patent families in other jurisdictions for potential overlap or infringement risks, especially if the claims are sufficiently broad.
4. Strategic Significance and Patent Lifecycle
Protection Duration: As a pharmaceutical patent filed over 20 years ago, it likely either is nearing expiry or has already expired in Japan, affording generic manufacturers market entry.
Strategic considerations:
- Patent expiry diminishes exclusivity but can inform R&D cycles for new formulations.
- Continuation or divisional applications could have been filed to extend protection geographically or scope-wise.
Patent landscape insights: The patent illustrates a focus on drug stability and delivery, key areas where incremental innovation remains vital. Companies can explore design-around strategies or patent licensing opportunities based on this patent.
5. Implications for Stakeholders
- Pharmaceutical Innovators: Need to analyze whether their formulations infringe on the specific features of JP3785365.
- Generic Manufacturers: Should facilitate assessment of patent expiry or licensing windows.
- Legal Professionals: Must evaluate claim scope against current and emerging prior art to advise on patent validity or infringement risks.
- R&D Entities: Can identify technological gaps to develop next-generation formulations that circumvent existing patents.
6. Conclusion and Key Takeaways
- JP3785365 provides targeted protection for specific drug formulations or processes, likely involving unique excipient combinations or manufacturing methods that improve drug stability or bioavailability.
- Its scope is deliberately balanced, protecting particular embodiments while leaving room for innovation.
- The patent landscape in Japan and internationally is dense, emphasizing the importance of detailed claim analysis and freedom-to-operate assessments.
- The patent’s potential expiry or upcoming expiration warrants attention, especially for market entry strategies or licensing negotiations.
- Strategic considerations must revolve around claim scope, patent validity, and ongoing innovation to maintain competitive advantage.
7. Frequently Asked Questions (FAQs)
Q1: What is the main technological innovation protected by JP3785365?
A1: The patent primarily protects a specific pharmaceutical formulation or manufacturing process that enhances drug stability or bioavailability, likely involving unique excipient combinations or physical forms.
Q2: How broad are the claims in JP3785365?
A2: The claims are moderately broad, covering certain formulations and processes while likely anchored by specific features to distinguish from prior art, allowing for some flexibility but also defining clear boundaries.
Q3: Can this patent be challenged for validity?
A3: Yes, if prior art demonstrates that the claimed features are not novel or inventive, a validity challenge can be mounted, especially considering the crowded patent landscape in drug formulation technology.
Q4: Does JP3785365’s scope overlap with similar patents held internationally?
A4: Potentially, yes. Similar formulations or processes may be protected elsewhere; a detailed comparison with global patent families is advised to identify infringement or licensing potentials.
Q5: When does the patent JP3785365 expire, and how does that impact market strategy?
A5: The patent, filed around 2005-2006, likely expires around 2025-2027 in Japan, after which generic competition may emerge, guiding R&D and licensing strategies accordingly.
References
- Japan Patent Office (JPO). Official Patent Document JP3785365.
- WIPO Patent Database. Patent family data and legal status.
- European Patent Office (EPO). Patent databases related to pharmaceutical formulations.
- United States Patent and Trademark Office (USPTO). Similar patents and priority documents.
- Patent Landscape Reports. (Various industry analyses on drug formulation patents).
End of Article
